Sign In
Buy AZN
$169.47
-2.14 (-1.25%)
At Close: Jul 13, 2026
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions
12:25pm, Monday, 13'th Jul 2026
When a late-stage clinical trial misses a primary endpoint, the market reaction rarely distributes evenly across the board. The fallout often reveals undeniable fundamental truths about single-asset e
AZN Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into AstraZeneca (AZN)
11:00am, Monday, 13'th Jul 2026
On July 9, 2026, AstraZeneca (NYSE: AZN) stock fell more than 8% premarket after the Company announced that the Phase III CARDIO-TTransform trial of Wainua mis
AZN Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into AstraZeneca (AZN)
10:07am, Monday, 13'th Jul 2026
NEW YORK--(BUSINESS WIRE)--On July 9, 2026, AstraZeneca (NYSE: AZN) stock fell more than 8% premarket after the Company announced that the Phase III CARDIO-TTransform trial of Wainua missed its primar
HSBC downgrades AstraZeneca after key trial failure
08:11am, Monday, 13'th Jul 2026
HSBC has downgraded AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) to 'hold' from 'buy', arguing that a recent trial failure has removed the central pillar of its bull case and left a tougher path ahead. The
UBS stays positive on AstraZeneca ahead of second-quarter results
07:36am, Monday, 13'th Jul 2026
UBS expects AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) to report solid second-quarter results later this month, though it sees little room for the drugmaker to raise full-year guidance. The bank reiterate
AstraZeneca Updates 2030 Sustainability Goals as AI and Emissions Cuts Take Center Stage
07:03pm, Saturday, 11'th Jul 2026
Astrazeneca NYSE: AZN told investors and analysts that it is continuing to embed sustainability into its business strategy while updating some of its 2030 targets to reflect growth and lessons learned
AstraZeneca's trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable?
01:00am, Saturday, 11'th Jul 2026
AstraZeneca posted a rare clinical trial failure on Thursday, sending shares down 6% to their worst day in over two years. Analysts estimate the trial miss wiped just 2-4% from their valuation models
Astrazeneca (AZN) Stock Dips While Market Gains: Key Facts
07:16pm, Friday, 10'th Jul 2026
The latest trading day saw Astrazeneca (AZN) settling at $171.61, representing a -3.85% change from its previous close.
Ionis, AstraZeneca Stumble in ATTR-CM Trial as Rivals Stand to Gain
11:30am, Friday, 10'th Jul 2026
Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and partner AstraZeneca Plc (NYSE:AZN) said on Thursday that their Phase 3 CARDIO-TTRansform study of eplontersen for transthyretin-mediated amyloid cardiomyop
AZN SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving AstraZeneca
09:00am, Friday, 10'th Jul 2026
/PRNewswire/ -- On July 9, 2026, AstraZeneca (NYSE: AZN) shares fell approximately 8.4% before the market opened after the Phase III CARDIO-TTransform trial of
AstraZeneca Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into AstraZeneca (AZN)
08:58pm, Thursday, 09'th Jul 2026
AstraZeneca (AZN) announced its key CARDIO-TTRansform Phase III trial missed its primary endpoint. SueWallSt notifies investors of a pending investigation into potential securities claims on behalf of
AstraZeneca And Ionis Pharma Rocked By Heart Disease Fail: Why You Shouldn't Panic
03:58pm, Thursday, 09'th Jul 2026
AstraZeneca PLC shares fell >6% after Wainua (eplontersen) failed its Phase 3 ATTR-CM trial, missing a major revenue opportunity. The stock of Ionis Pharmaceuticals, Inc., developer of eplontersen and
AstraZeneca's Stock Drops on Wainua's Setback in ATTR-CM Study
10:56am, Thursday, 09'th Jul 2026
AZN shares tumble after Wainua missed the primary endpoint in a late-stage ATTR-CM study, raising questions about its expansion into a larger market.
AstraZeneca's Wainua failure hurts credibility more than valuation, Jefferies warns
09:29am, Thursday, 09'th Jul 2026
The damage to AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) from Wainua's trial failure is less about the numbers than about a dent to management's credibility, according to Jefferies. The shares fell 9% and
5 Things to Know Before the Stock Market Opens on Thursday
08:35am, Thursday, 09'th Jul 2026
Stock futures are slightly higher this morning as investors monitor developments in the Middle East; PepsiCo's results narrowly beat Wall Street estimates as strength in international markets offset s
